Related Experiment Videos
Early Vasoactive-Inotropic Response Trajectories After Polymyxin B Hemoperfusion in Septic Shock: A Single-Center
Wei-Hung Chang1,2, Kuan-Pen Yu1, Li-Kuo Kuo1
1Department of Critical Care Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
Purpose:
To characterize early weight-indexed vasoactive-inotropic score (VIS) trajectories after polymyxin B hemoperfusion (PMX-HP) in septic shock and examine association with 28-day mortality.
Methods:
We retrospectively studied 64 adult intensive care unit patients treated with PMX-HP from July 2013 to December 2019. VIS was calculated after body-weight indexing. T1 was before the first session, T2 after the final session, and T3 24 h later. Immediate sustained response required T2 reduction without T3 rebound; delayed response required later reduction; adverse trajectory included no response, rebound, or death before T3.
Results:
Twenty-nine patients (45.3%) had immediate sustained response, two (3.1%) delayed response, and 33 (51.6%) adverse trajectory. Twelve died before planned T3. Among 60 verified timestamps, median shock-to-treatment interval was 17.3 h (interquartile range, 6.6-27.7); median session duration was 2.0 h (interquartile range, 2.0-2.3). Twenty-eight-day mortality was 31.0%, 0.0%, and 63.6%, respectively. Adverse trajectory had higher unadjusted odds of 28-day mortality than immediate sustained response (odds ratio, 3.89; 95% confidence interval, 1.35-11.22). In an age- and Acute Physiology and Chronic Health Evaluation II-adjusted model excluding delayed response, the adjusted odds ratio was 4.17 (95% confidence interval, 1.35-12.86; p = 0.013). Landmark sensitivity analysis was directionally consistent but imprecise.
Conclusions:
Failure to achieve sustained early reduction in weight-indexed vasoactive support, rebound, or death before reassessment identified an adverse early clinical course. Findings support cautious risk stratification, not causal evidence of treatment efficacy.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Acute Kidney Injury IV: Diagnostic Studies and Prevention